Skip To Main Content
- Study Title
- Real-World Impact of Subcutaneous Long-Acting Injectable Olanzapine Suspension (TV-44749) in Adult Patients With Schizophrenia: RADIANCE Study
- Teva Identifier
- TV44749-CNS-40299
- ClinicalTrials.gov Identifier
- NCT07913100
- Study Status
- Not yet recruiting
- Trial Condition(s)
- Schizophrenia
- Interventions
- Drug: TV-44749
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years and older
- Trial Duration
- March 30, 2027 - May 31, 2031
- Phase
- 4